Ocular FIP treatment comes into sharper clinical focus

CURRENT FULL VERSION: Cats with ocular feline infectious peritonitis are no longer being treated in a clinical gray zone quite the way they were even two years ago. Emerging case-series data and updated guidance are helping define how remdesivir and GS-441524 are being used in these patients, while legal access to compounded oral GS-441524 in the U.S. has changed the treatment landscape. Together, those developments are giving veterinarians a clearer path for managing one of the more complicated presentations of FIP. (pmc.ncbi.nlm.nih.gov)

The recent VetGirl discussion on ocular FIP lands in the middle of a fast-moving period for feline infectious peritonitis care. FIP was long considered almost uniformly fatal, but that changed as antiviral protocols built around GS-441524 and remdesivir showed strong survival and remission rates in studies from Australia, the UK, and elsewhere. In the U.S., access lagged behind the science, and many pet parents turned to unregulated online sources before compounded oral GS-441524 became available by prescription on June 1, 2024. FDA’s Center for Veterinary Medicine said it does not intend to enforce new animal drug approval requirements for patient-specific compounded GS-441524 prescribed for FIP under the conditions in Guidance for Industry #256. (vet.cornell.edu)

For ocular disease specifically, the key new evidence is a 2024 observational case series describing 20 cats with FIP-associated ocular involvement treated with remdesivir, GS-441524, or both. Seventeen cats began with injectable remdesivir, three started with oral GS-441524, and treatment was generally continued for 84 consecutive days unless the cat died or was euthanized earlier. Most cats in the series received higher-intensity antiviral dosing: over half were started on 15 to 20 mg/kg remdesivir, and among cats transitioned to oral GS-441524, 14 of 17 received 15 to 22 mg/kg. The authors said these higher doses reflected both prior literature and clinical experience suggesting ocular and neurologic FIP need more aggressive dosing. VetGirl’s review helps explain why clinicians are treating these cats differently: ocular involvement is seen much more often in non-effusive FIP than in wet disease, can occasionally be the dominant presenting feature, and may show up as anterior uveitis, keratic precipitates, iris color change, dyscoria, anisocoria, hyphema, hypopyon, fibrinous exudate, retinal lesions, hemorrhage, vascular tortuosity, detachment, or perivascular cuffing. Those findings can be unilateral or bilateral and may be the first obvious clue to systemic infection. (pmc.ncbi.nlm.nih.gov)

That approach aligns with broader guidance. ABCD’s FIP guideline says higher dosages are indicated when ocular and/or neurologic signs are present, and notes that oral GS-441524 is usually favored over injectable remdesivir when the cat can tolerate oral medication. Clinician-facing summaries have made the same point, arguing that ocular and neurologic cases likely need larger doses because treatment has to reach tissues protected by the blood-ocular and blood-brain barriers as those barriers heal. In practical terms, that means ocular FIP is not just “regular FIP with eye lesions.” It may require different expectations around dose selection, route, hospitalization at the start of care, and monitoring for response. More broadly, recent VetGirl and podcast discussions on FIP have emphasized that treatment success rates are now often reported in the 85% to 90% range, but diagnosis in practice is still usually presumptive rather than definitive, making pattern recognition, clinicopathologic data, imaging, fluid analysis, and response to therapy part of the real-world decision-making process. (abcdcatsvets.org)

There are still important caveats. The ocular case series was observational and small, so it helps describe real-world treatment patterns more than it settles the question of an optimal protocol. The authors also flagged uncertainty around adjunct anti-inflammatory therapy, noting that the benefit of systemic anti-inflammatory drugs alongside antivirals remains unclear and should be weighed carefully, particularly in critically ill cats. And while success rates with licensed or compounded pathways are encouraging, the evidence base still includes heterogeneous dosing schemes, variable case definitions, and evolving formulations. Another open question is duration. The traditional 12-week course remains the default, especially for tissues that are harder for drugs to penetrate, including the eye and central nervous system. But newer discussion in the profession is shifting toward whether higher-dose induction protocols and more objective stopping criteria could safely shorten therapy in selected cats. In that context, investigators have been evaluating acute phase proteins such as serum amyloid A and alpha-1 acid glycoprotein, along with the albumin:globulin ratio, as possible tools to complement clinical improvement when deciding whether treatment can end. (pmc.ncbi.nlm.nih.gov)

Industry and academic commentary has generally framed the big story as access plus standardization. Cornell called the arrival of compounded oral GS-441524 in the U.S. a major step forward for a previously untreatable disease, and AAHA reported that Stokes Pharmacy began selling a compounded prescription product on June 1, 2024. At the same time, researchers studying at-home treatment warned that unlicensed products varied significantly from label claims, underscoring why veterinarians have pushed for regulated prescribing channels and more formal protocols. VetGirl’s broader FIP updates also reinforce that the disease still begins with common feline enteric coronavirus exposure in many young cats, especially in multicat environments, before a small subset develop the macrophage-associated mutated form that drives vasculitis and the familiar wet, dry, ocular, and neurologic presentations seen in practice. (vet.cornell.edu)

Why it matters: For veterinarians, ocular FIP is becoming a more manageable clinical problem, but also a more protocol-sensitive one. The main shift is not simply that treatment exists; it’s that clinicians now have better support for using higher-dose antiviral strategies in ocular cases and a legal U.S. supply pathway that reduces dependence on inconsistent gray-market products. That should improve confidence in diagnosis-to-treatment workflows, help practices counsel pet parents earlier, and make it easier to distinguish treatment failure from formulation failure. It also raises the bar for monitoring, because these patients may need longer conversations about dose intensity, appetite, route changes, ocular exams, neurologic crossover risk, liver enzyme monitoring, cost, and the fact that visible early improvement does not necessarily mean viral clearance. If biomarker-guided treatment decisions prove reliable, they could eventually make those conversations more precise. (pmc.ncbi.nlm.nih.gov)

What to watch: The next phase will likely focus on finer points rather than proof of concept, including ocular-specific dosing thresholds, when to split daily doses, how to use adjunct anti-inflammatory therapy safely, and whether shorter treatment courses can work in selected cases without increasing relapse risk. Expect continued interest in high-dose induction strategies, objective monitoring tools such as acute phase proteins and A:G ratio trends, and clearer criteria for when treatment can be stopped rather than simply continued to 84 days by default. (pmc.ncbi.nlm.nih.gov)